Dianthus Therapeutics Announces Early GO Decision Following Interim Responder Analysis in Phase 3 CAPTIVATE Trial of Claseprubart in Chronic Inflammatory Demyelinating ...

Early GO decision reached ahead of Q2’26 guidance based on GO criteria of 20 confirmed responders achieved with less than 40 planned participants ...

NovelMed Therapeutics Announces Regulatory Clearance for Subcutaneous Ruxoprubart and Reports Positive Phase II Intravenous Monotherapy Results in PNH

Precision Bb Targeting, Robust Efficacy, Transfusion Independence, Excellent Safety in Phase II PNH Study, and Subcutaneous AdministrationKey ...

Dianthus Therapeutics, Inc.: Dianthus Therapeutics Announces Early GO Decision Following Interim Responder Analysis in Phase 3 CAPTIVATE Trial of Claseprubart in Chronic ...

Early GO decision reached ahead of Q2'26 guidance based on GO criteria of 20 confirmed responders achieved with less than 40 planned participants completing open-label Part A Key objectives achieved: ...
Investor's Business Daily on MSN

Dianthus Therapeutics has appreciated 12-fold over two years. What's going on?

Dianthus Therapeutics stock shot higher Monday after the company said it would advance its experimental CIDP treatment.
Frontiers

Unveiling metabolite and sensory receptor pathways to modulate autoimmune inflammation

Autoimmune and autoinflammatory diseases arise from complex interactions between host genetic susceptibility and environmental factors, particularly the gut ...